Mendelian DisordersNCT02021734
Genetics of Mendelian Diseases in Qatar
An observational study of Mendelian Disorders, run by Weill Medical College of Cornell University at 1 site in Qatar.
Trial summary
There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Mendelian Disorders
- How many people
- 400 participants
- Where
- 1 siteQatar
- Study dates
- 19 Nov 2012to Feb 2025
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: physicians and by thorough review of the literature to establish that the disease is indeed Mendelian and with unknown gene.
Who may be able to join
- All included individuals must provide informed consent
- All genetic disorders are included
- All ethnic backgrounds are accepted
- Disease must be genetic with no evident environmental cause
- Evidence of Mendelian Transmission determined by fulfilling one of the following criteria:
- Multiple affected family members (at least first degree relative with disease)
Show all 11Show fewer
- History of consanguinity
- Severe disease in newborn in the absence of family history
- Sydromic disease in single individuals
- Congenital abnormality affecting major organ system(s)
- Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension)
Who cannot join
- Individuals who do no consent to be included
- Mendelian disease for which a gene mutation has already been identified
- Individuals for which a molecular diagnosis has already been established by alternative method
- Disease for which an environmental factor is most likely the cause
- Disease for which late age of onset rule out Mendelian transmission
- Common diseases for which late age of onset rule out Mendelian transmission
Trial locations and contacts
1 site in 1 country.
About this study
There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools.
Read the detailed description
There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools. These include high-throughput sequencing and genotyping along with the necessary bioinformatics analyses that will lead to the discovery of the causes of most inherited diseases in the region.The secondary objective will be to build a comprehensive catalogue of genetic variation in the Arab world. This will include all detected mutations, not only the subset that are causing disease (from primary objective), but also known trait-altering mutations as well as general diversity on the DNA level among human populations of this region. This catalogue can become a widely useful resource for many projects down the road, as it relies on anonymizing individual samples and instead displaying data in aggregate as the cohorts of collected samples grow over the years.
The study will include all genetic disorders from all ethnic backgrounds but Mendelian disease for which a gene mutation has already been identified will be excluded.
Evidence of Mendelian Transmission determined by fulfilling one of the following criteria:
Multiple affected family members (at least first degree relative with disease) History of consanguinity Severe disease in newborn in the absence of family history Sydromic disease in single individuals Congenital abnormality affecting major organ system(s) Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension)
- Conditions
- Mendelian Disorders
What is being measured
The primary outcome is the main question the study is designed to answer.
Next generation sequencing
Use next generation sequencing to detect novel disease causing mutations
Measured: 1 hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2013 (estimated)
- Study start19 Nov 2012
- Primary completionJun 2022
- Study completionFeb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mendelian DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Family based
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Weill Medical College of Cornell University
- Sponsor type
- University, hospital or other
- Collaborators
- Hamad Medical Corporation, Weill Cornell Medical College in Qatar
- Responsible party
- Sponsor
- Investigators
- Ronald Crystal, MD, Principal investigator, Weill Medical College of Cornell University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02021734
- Sponsor's protocol ID
- 13-00065 [JIRB]
- Other IDs
- 12217/12
- Status last verified
- Nov 2025
- First submitted
- 22 Nov 2013
- Last updated
- 17 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No